Landmark collaboration will focus on empowering women’s wellbeing and enhancing women’s health awareness in Lebanon and the region
Beirut Lebanon, August 2023: Organon, a global healthcare company dedicated to making a difference in women’s health, is pleased to announce the signing of a Memorandum of Understanding (“MoU”) with Bellevue Medical Center (“BMC”), Lebanon’s leading tertiary care center with women’s health and fertility as center of excellence.
The MoU signifies a momentous leap in advancing women’s health and bolstering awareness in Lebanon and the broader region, particularly during a period of unparalleled challenges in women’s health. The MoU was signed by Rami Koussa Associate Vice President for the MENAT at Organon, and Nayef Maalouf, President and CEO of BMC, in the presence of Kevin Ali, CEO of Organon
Commenting on the partnership, Organon CEO, Kevin Ali, said: “The signing of this MOU is just the beginning of a journey towards a brighter future for women’s health in Lebanon. Organon and BMC are committed to fostering sustainable partnerships and engaging with stakeholders from various sectors to drive progress in women’s health. Our hope is that this collaboration will activate the ecosystem required to advance women’s health and advocate for meaningful policy reforms to address critical health challenges faced by women.”
Building on its foundation of diverse collaborations, Organon has actively driven women’s health initiatives in the MENAT region. The signing of this MoU underscores Organon’s commitment to broaden collaborations that advance women’s health. As Organon continues its mission, it seeks to unite with various stakeholders across the entire ecosystem to enrich its impact and jointly raise women’s healthcare standards. Organon believes that empowering women through cross-industry partnerships and collaborations can significantly reshape healthcare norms and positively impact lives across the region.
President and CEO of Bellevue Medical Center, Nayef Maalouf added: “In recent years, the economic and financial crisis in Lebanon, compounded by the Covid-19 pandemic, as well as the tragic Beirut port explosion have significantly impacted the health of the population. Women have borne the brunt of these crises, facing barriers to healthcare access, and experiencing widening gender gaps in various aspects of their lives. With the signing of this MoU between Organon and BMC, we aim to prioritize innovation in women’s health, close gender gaps, and promote gender equality worldwide in line with the United Nations Development Goals.”
Under the framework of cooperation and collaboration between Organon and BMC, the MoU focuses on three key areas:
- Scientific and Clinical Training: Organon will provide at BMC comprehensive training to healthcare professionals, focusing on holistic women’s health lifecycle management. This will cover reproductive health, menopause, and other relevant aspects to enhance the quality of care and support.
- Enhanced Fertility and Contraception Education: Organon will share expertise in fertility and contraception education, empowering women to make informed family planning choices. BMC will integrate this education into existing maternity services and reproductive healthcare programs, improving access to family planning options and decision-making.
- Social Media Awareness Campaigns: Jointly conducting social media awareness campaigns, they aim to support women’s healthcare journey and raise awareness about unmet health needs. This initiative fosters a supportive community, empowering women to take control of their health and achieve positive outcomes.
Organon and BMC are steadfast in their dedication to driving meaningful change and improving the health and wellbeing of women in Lebanon and the wider region. This landmark initiative marks a pivotal moment in the region’s healthcare landscape as Organon takes the lead in addressing the unmet needs of women.
About Organon
Organon is a global healthcare company formed through a spin-off from Merck, (NYSE: MRK), known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Organon has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the women’s health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in innovation and future growth opportunities in women’s health. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,500 employees with headquarters located in Jersey City, New Jersey.
For more information, visit http://www.organon.com and connect with us on LinkedIn.